Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab - Concepedia

Concepedia

Publication | Open Access

Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab

DOI Full Paper Access

19

Citations

18

References

2018

Year

Héctor Ortega, Andrew Menzies‐Gow, Jean‐Pierre Llanos, Mark Forshag, Frank C. Albers, Necdet B. Gunsoy, Eric Bradford, Steven W. Yancey, Monica Kraft

Advances in Therapy

Abstract

GlaxoSmithKline (study ID 208091).

References

	Year	Citations
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION Romain Pauwels Arerugī/Arerugi AsthmaPreventive MedicineAllergyGlobal HealthInternational Health	1996	10.1K
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma Kian Fan Chung, Sally E. Wenzel, Jan Brożek, European Respiratory Journal AsthmaAllergyAsthma TherapyAllergy MedicineRespiratory Diseases	2013	3.8K
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma Héctor Ortega, Mark C. Liu, Ian Pavord, New England Journal of Medicine	2014	2.2K
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial Ian Pavord, Stephanie Korn, Peter Howarth, The Lancet AsthmaSevere Eosinophilic AsthmaAllergyMedicineAllergy Medicine	2012	2.2K
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma Pranabashis Haldar, Christopher E. Brightling, Beverley Hargadon, New England Journal of Medicine	2009	1.9K
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma Elisabeth H. Bel, Sally E. Wenzel, Philip J. Thompson, New England Journal of Medicine	2014	1.6K
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia Parameswaran Nair, Márcia Margaret Menezes Pizzichini, Melanie Kjarsgaard, New England Journal of Medicine	2009	1.3K
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial J. Mark FitzGerald, Eugene R. Bleecker, Parameswaran Nair, The Lancet AsthmaRheumatologyPlacebo-controlled Phase 3ImmunologyClinical Trials	2016	1.3K
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial Eugene R. Bleecker, J. Mark FitzGerald, Pascal Chanez, The Lancet AsthmaAllergyPlacebo-controlled Phase 3Clinical TherapeuticPharmacology	2016	1.3K
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials Mario Castro, James Zangrilli, Michael E. Wechsler, The Lancet Respiratory Medicine AsthmaAllergyAllergy MedicineClinical TrialsEosinophilic Disorder	2015	1.2K

Page 1